Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease

Modern Pathology

Volumn 10, Issue 7, 1997, Pages 645-649

  Dueñas Gonzalez, Alfonso ^a   Isales, Carlos M ^b   Del Mar Abad Hernandez, María ^a   Gonzalez Sarmiento, Rogelio ^a   Sangueza, Omar ^b   Rodriguez Commes, José ^a,c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Breast cancer; Metastasis; Nitric oxide synthase; nm23

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANGIOGENESIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST METASTASIS; ENZYME INDUCTION; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MONOMERIC GTP-BINDING PROTEINS; NITRIC OXIDE SYNTHASE; NUCLEOSIDE-DIPHOSPHATE KINASE; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 0342894681     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
2. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
3. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature. Br J Pharmacol 1992;107:1092-5.
4. Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology, and clinical relevance. Eur J Clin Invest 1991;21: 361-74.
5. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995;72:41-4.
6. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994;54:1352-4.
7. Rosbe KW, Prazma J, Petrusz P, Mims W, Ball SS, Weissler MC. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 1995;113:541-9.
8. Dong Z, Staroselsky AH, Qi X, Xie K, Fidler IJ. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res 1994;54:789-93.
9. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995;181:1333-43.
10. Liu RH, Hotchkiss JH. Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat Res 1995;339:73-89.
11. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 1994;305:253-64.
12. Fisher ER. Prognostic and therapeutic significance of pathological features of breast cancer. NCI Monogr 1986;1:29-34.
13. Lloyd RV, Jin L, Qian X, Zhang S, Scheithauer BW. Nitric oxide synthase in the human pituitary gland. Am J Pathol 1995;146:86-94.
14. Royds JA, Stephenson TJ, Rees RC, Shorthouse AJ, Silcocks PB. nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 1993;85:727-31.
15. Moncada S, Radomski MW, Palmer RM. Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988;37:2495-501.
16. Moncada S, Higgs EA, Palmer RM. Characterization and biological significance of endothelium-derived relaxing factor. Biochem Soc Trans 1988;16:484-6.
17. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 1993;27:1380-2.
18. Schmidt HH, Pollock JS, Nakane M, Forstermann U, Murad F. Ca2+/calmodulin-regulated nitric oxide synthases. Cell Calcium 1992;13:427-34.
19. Moncada S, Palmer RM. Biosynthesis and actions of nitric oxide. Semin Perinatol 1991;15:16-9.
20. Xie K, Huang S, Dong Z, Gutman M, Fidler IJ. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res 1995;55:3123-31.
21. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A 1995;92:4392-6.
22. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990;101: 746-52.
23. Palmer RM, Bridge L, Foxwell NA, Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br J Pharmacol 1992;105:11-2.
24. Buttery LD, Springall DR, Andrade SP, Riveros-Moreno V, Hart I, Piper PJ, et al. Induction of nitric oxide synthase in the neo-vasculature of experimental tumours in mice. J Pathol 1993;171:311-9.
25. Dameron KM, Volpert OV, Tainsky MA, Bouck N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994;59:483-9.
26. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
27. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9:963-9.Book Review